A Phase 1, Randomized, Blinded, Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent
Latest Information Update: 17 Jan 2020
At a glance
- Drugs Cotadutide (Primary)
- Indications Obesity
- Focus Adverse reactions
- Sponsors MedImmune
- 11 Jun 2019 Results evaluated the safety, tolerability, pharmacokinetics, and immunogenicity of MEDI0382 in overweight/obese subjects presented at the 79th Annual Scientific Sessions of the American Diabetes Association
- 16 Apr 2018 Status changed from recruiting to completed.
- 28 Feb 2018 Planned End Date changed from 18 May 2018 to 4 May 2018.